ALK and non-small cell lung carcinoma: An updated analysis of the Keynote‐189 trial data reported a median OS of 22.0 months and a PFS of 11.1 months for 35 nonsquamous BM NSCLC patients without sensitizing EGFR/ALK alterations while excluding symptomatic patients with CNS metastasis.